An observational study in Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension and Right Ventricular Dysfunction, sponsored by Azienda Ospedaliero-Universitaria Careggi. Recruiting at 16 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Azienda Ospedaliero-Universitaria Careggi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Venous Thromboembolism with a site in Italy — 10 open to participants now, 13 under way, 3 of them phase 3. Venous Thromboembolism · Italy.
Among the 74 studies in Venous Thromboembolism with a site in Italy, this one is the 10th largest by planned enrollment of the 23 observational ones that give a count, is the only one that started in 2026, is one of 23 observational ones, reaches primary completion later than 10 of the 12 other live ones, and was the 74th registered.
714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.
Browse Venous Thromboembolism studies →10 of the 74 studies in Venous Thromboembolism with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
University Of Perugia · Sites in Italy
Ages 18+
Ottawa Hospital Research Institute · Sites in Italy, Canada, France and 3 more countries
Ages 18+
Arianna Anticoagulazione Foundation · Sites in Italy
Ages 75+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Italy, Netherlands, Spain
Ages 18–120
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 34 · Phase 4 4
First in 1998; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 700 across 283 observational studies indexed under Venous Thromboembolism.
Median enrollment 839 across the 50 interventional studies, 2,040 across the 23 observational. Of the 58 that completed or were terminated, 23 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 74 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliero-Universitaria Careggi is the lead sponsor of 78 studies on the registry; 23 are open to participants now.
Azienda Ospedaliero-Universitaria Careggi has 1 study filed under Venous Thromboembolism — fewer than ten, so there is no comparison to draw.
2 of the studies in Venous Thromboembolism with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07228663Phase 3McMaster UniversityHip Fracture Surgery Arterial and Venous Thrombotic Events Prevention | 2027-07-01 |
| NCT02832245Manuel MonrealComputerized Registry of Patients With Venous Thromboembolism (RIETE) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 74 studies in Venous Thromboembolism with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PERSEUS is an academic, investigator-initiated, multicenter observational registry of adults with acute pulmonary embolism (PE), promoted by Azienda Ospedaliero-Universitaria Careggi (Florence, Italy). It collects data generated during routine care across the whole course of the disease: pre-hospital care when available, emergency department presentation, the hospital stay (including bedside reassessments in the first 48 hours when performed as part of care) and follow-up up to 5 years. The registry has a retrospective cohort (patients diagnosed from 1 January 2023 until local ethics committee approval, with data taken from medical records) and a prospective cohort (consecutive patients enrolled after approval). Taking part in the registry does not change patient care: all tests and treatments are decided by the treating physicians. The registry aims to describe how acute PE is managed in everyday practice and how often patients die (from any cause and from PE), deteriorate hemodynamically, have recurrent venous thromboembolism or bleeding, and develop long-term complications such as chronic thromboembolic pulmonary hypertension. The database also supports ancillary analyses with separate pre-specified analysis plans, such as the evaluation of existing risk-stratification tools.
BACKGROUND AND SCIENTIFIC RATIONALE
Pulmonary embolism (PE) represents a major cause of emergency department (ED) presentation, critical care admission, and early mortality. Despite advances in diagnostic algorithms and therapeutic strategies, intermediate- and high-risk PE patients remain challenging to risk-stratify dynamically during the acute phase. Current prognostic tools often rely solely on baseline single-point parameters, neglecting acute pathophysiological changes during the initial 48 hours of treatment. The PERSEUS Registry is designed to bridge this gap by capturing comprehensive, granular real-world data spanning the acute presentation, dynamic in-hospital course, and long-term surveillance.
STUDY DESIGN AND COHORTS
Time perspective: ambispective (retrospective and prospective cohorts, described below).
PERSEUS is an observational, ambispective, multicenter registry comprising two distinct phases:
STUDY SETTING AND CLINICAL CONTINUUM OF CARE
Data collection spans the entire continuum of clinical care across participating academic, tertiary, and regional hospitals:
OUTCOMES
Outcome definitions and time frames are reported in the Outcome Measures section.
DATA MANAGEMENT, QUALITY ASSURANCE, AND ETHICAL GOVERNANCE
Data collection is centralized using an electronic Case Report Form (eCRF) deployed on the REDCap (Research Electronic Data Capture) platform hosted on secure institutional servers at Azienda Ospedaliero-Universitaria Careggi (Florence, Italy).
The criteria were revised on the registry on Oct 7, 2026. See what changed
Consecutive adults with objectively confirmed acute pulmonary embolism diagnosed at participating hospitals, from emergency department presentation through hospitalization, including patients presenting with obstructive shock or cardiac arrest.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Consecutive adults with objectively confirmed acute pulmonary embolism, in two cohorts: a retrospective cohort (diagnoses from 1 January 2023 until local ethics committee approval; data abstracted from medical records) and a prospective cohort (consecutive enrollment after approval, for 5 years; data collected during routine care).
Other: Routine clinical care (no study intervention)
Observational registry. Diagnostic and therapeutic management (laboratory tests, imaging, bedside ultrasound, anticoagulation, reperfusion and hemodynamic support) is entirely at the discretion of the treating physicians, according to routine institutional pathways and international guidelines. The registry only collects data generated in routine care.
Also known as: Routine Clinical Practice, Usual Care
All-cause mortality at 30 days
Proportion of patients who die from any cause within 30 days of the objectively confirmed diagnosis of acute pulmonary embolism. Vital status is ascertained from hospital records, review of clinical documentation and, when needed, regional mortality registries.
Time frame: 30 days after diagnosis
PE-related mortality at 30 days
Proportion of patients whose death within 30 days is adjudicated as a direct consequence of the index or a recurrent pulmonary embolism (PE). Fatal PE is defined as death occurring after objectively confirmed PE (index or recurrent event) in the absence of other identifiable causes, or confirmed at autopsy. For deaths occurring at home, information on the cause of death is actively sought.
Time frame: 30 days after diagnosis
Hemodynamic decompensation
Proportion of patients with new occurrence, after the initial assessment, of at least one of: persistent hypotension (systolic blood pressure \<90 mmHg for 15 minutes or longer) or shock; need for continuous vasopressor or inotrope infusion; invasive mechanical ventilation; cardiac arrest; rescue reperfusion therapy (systemic, catheter-directed or surgical) for clinical deterioration. Reperfusion given as the initial treatment strategy is not counted as an event.
Time frame: From diagnosis to hospital discharge or day 30, whichever comes first
All-cause mortality during follow-up
Proportion of patients who die from any cause during follow-up.
Time frame: 3 months, 12 months, and annually up to 5 years after diagnosis
PE-related mortality during follow-up
Proportion of patients whose death during follow-up is adjudicated as a direct consequence of the index or a recurrent pulmonary embolism, as defined for the 30-day PE-related mortality outcome.
Time frame: 3 months, 12 months, and annually up to 5 years after diagnosis
Recurrent venous thromboembolism
Proportion of patients with any new episode of pulmonary embolism or deep vein thrombosis (lower or upper limb, proximal or distal) confirmed by objective testing. Superficial vein thrombosis is not counted.
Time frame: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
Major bleeding (ISTH criteria)
Proportion of patients with major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH): overt bleeding that is fatal; or occurs in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome); or causes a fall in hemoglobin of 2 g/dL (1.24 mmol/L) or more, or leads to transfusion of two or more units of whole blood or red cells. Major bleeding is additionally classified as life-threatening if it is extracranial bleeding causing shock or intracranial hemorrhage with a Glasgow Coma Scale score below 14.
Time frame: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
Clinically relevant non-major bleeding
Proportion of patients with bleeding not meeting the criteria for major bleeding but requiring medical intervention, unscheduled contact with a physician, or temporary cessation of antithrombotic therapy.
Time frame: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
Chronic thromboembolic pulmonary hypertension (CTEPH)
Proportion of patients with CTEPH diagnosed during routine follow-up: mean pulmonary arterial pressure \>20 mmHg, pulmonary arterial wedge pressure ≤15 mmHg and pulmonary vascular resistance \>2 Wood units at right heart catheterization, with mismatched perfusion defects after at least 3 months of therapeutic anticoagulation (2022 ESC/ERS criteria). Diagnostic tests are performed only when clinically indicated.
Time frame: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
Persistent functional limitation after pulmonary embolism (post-PE syndrome)
Persistent or worsened exertional dyspnea compared with pre-event status, modified Rankin Scale score, and six-minute walk distance when performed in routine care.
Time frame: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
Plan to share: Yes — Pseudonymized individual participant data underlying published results may be shared with qualified researchers for methodologically sound proposals that fall within the scientific scope of the registry and do not overlap with analyses planned by the PERSEUS investigators. Sharing requires approval by the PERSEUS Steering Committee, approval by the competent ethics committee and a data transfer agreement with Azienda Ospedaliero-Universitaria Careggi, in compliance with the GDPR and the Italian Privacy Code.
Supporting information: Study protocol
Time frame: Data will become available beginning 12 months after formal publication of the primary registry outcomes manuscript and will remain accessible for a period of 5 years.
Access criteria: Access requests must be submitted in writing to the Principal Investigator (simone.vanni@unifi.it) and the PERSEUS Steering Committee, including a detailed scientific protocol and statistical analysis plan. Proposals will be evaluated for scientific merit, feasibility, ethical compliance, and non-redundancy by the Steering Committee. Prior to data release, requestors and their home institutions must sign a formal Data Transfer Agreement (DTA) with Azienda Ospedaliero-Universitaria Careggi and obtain appropriate local ethical approval.
Started Jun 2026 (actual). Primary completion is estimated for Jul 2031, 61 months after the start.
Of 97 non-industry observational studies under Venous Thromboembolism, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 61 months is above that.
Counting every sponsor, half of 118 studies reached it within 45 months; a quarter within 23 and three quarters within 75.
Start moved once since we started tracking on Sep 25, 2026: Jan 2023 → Jun 2026, on Oct 7, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliero-Universitaria Careggi